Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Oropharyngeal Neoplasms 6Nasopharyngeal Carcinoma 4Mesothelioma, Malignant 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Mouth Neoplasms 3Lymphoid Interstitial Pneumonia 3Laryngeal Neoplasms 3Carcinoma 3Adenocarcinoma of Lung 3Vaginal Neoplasms 2Triple Negative Breast Neoplasms 2Tongue Neoplasms 2Ovarian Neoplasms 2Hypopharyngeal Neoplasms 2Ganglioneuroblastoma 2Carcinoma, Transitional Cell 2Brenner Tumor 2Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Solitary Fibrous Tumor, Pleural 1Sinonasal Squamous Cell Carcinoma 1Salivary Gland Neoplasms 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

Specimen Handling 6Magnetic Resonance Spectroscopy 4Gemcitabine 3Biopsy 3eribulin 2cabozantinib 2atezolizumab 2pembrolizumab 1erdafitinib 1enfortumab vedotin 1carotuximab 1avelumab 1Watchful Waiting 1Platinum 1Observation 1Nivolumab 1Lenalidomide 1Ipilimumab 1Interleukin-7 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Contrast Media 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 1Bortezomib 1Bevacizumab 1Arsenic Trioxide 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Ureteral Neoplasms × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT00942331 2023-10-16

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 3 Completed
506 enrolled 13 charts
Genitourinary

Carcinoma, Transitional Cell, Prostatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡